MA43106B1 - Traitement de l'oligo-ovulation associée à la stéatose hepatique - Google Patents

Traitement de l'oligo-ovulation associée à la stéatose hepatique

Info

Publication number
MA43106B1
MA43106B1 MA43106A MA43106A MA43106B1 MA 43106 B1 MA43106 B1 MA 43106B1 MA 43106 A MA43106 A MA 43106A MA 43106 A MA43106 A MA 43106A MA 43106 B1 MA43106 B1 MA 43106B1
Authority
MA
Morocco
Prior art keywords
oligo
treatment
hepatic steatosis
ovulation
composition
Prior art date
Application number
MA43106A
Other languages
English (en)
Other versions
MA43106A (fr
Inventor
Lourdes Ibáñez
Zegher Francis De
Original Assignee
Univ Leuven Kath
Sant Joan De Deu Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath, Sant Joan De Deu Hospital filed Critical Univ Leuven Kath
Publication of MA43106A publication Critical patent/MA43106A/fr
Publication of MA43106B1 publication Critical patent/MA43106B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une méthode et une composition à utiliser pour traiter un état pathologique qui bénéficie de la réduction de graisse viscérale et/ou hépatique, notamment le syndrome des ovaires polykystiques chez les adolescentes ou les femmes en âge de procréer, la méthode et la composition impliquant l'utilisation de spironolactone, de pioglitazone et de metformine.
MA43106A 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique MA43106B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (fr) 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hépatique

Publications (2)

Publication Number Publication Date
MA43106A MA43106A (fr) 2021-05-05
MA43106B1 true MA43106B1 (fr) 2021-09-30

Family

ID=55130283

Family Applications (2)

Application Number Title Priority Date Filing Date
MA054412A MA54412A (fr) 2015-10-27 2016-10-27 Traitement d'excès de graisse hépatique et/ou viscérale
MA43106A MA43106B1 (fr) 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA054412A MA54412A (fr) 2015-10-27 2016-10-27 Traitement d'excès de graisse hépatique et/ou viscérale

Country Status (24)

Country Link
US (2) US20190060328A1 (fr)
EP (2) EP3368044B1 (fr)
JP (2) JP6999903B2 (fr)
KR (1) KR102608158B1 (fr)
CN (2) CN108778285A (fr)
AR (1) AR106505A1 (fr)
AU (1) AU2016344737C1 (fr)
BR (1) BR112018008496A2 (fr)
CA (1) CA3003076C (fr)
DK (1) DK3368044T3 (fr)
ES (1) ES2883282T3 (fr)
GB (1) GB201518979D0 (fr)
HU (1) HUE055778T2 (fr)
IL (1) IL258876B (fr)
LT (1) LT3368044T (fr)
MA (2) MA54412A (fr)
MX (2) MX384040B (fr)
PL (1) PL3368044T3 (fr)
RS (1) RS62764B1 (fr)
RU (1) RU2745606C2 (fr)
SI (1) SI3368044T1 (fr)
TW (1) TWI791420B (fr)
UY (1) UY36967A (fr)
WO (1) WO2017072243A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086045A1 (fr) 2017-12-19 2019-06-27 Akouos, Inc. Administration d'anticorps therapeutiques mediee par aav a l'oreille interne
EP3829546A1 (fr) 2018-08-02 2021-06-09 Hospital Sant Joan de Deu Formulation à libération immédiate d'une triple combinaison d'ingrédients pharmaceutiques actifs utile dans le traitement du syndrome des ovaires polykystiques
EP4007814A1 (fr) 2019-07-26 2022-06-08 Akouos, Inc. Méthodes de traitement de la perte auditive à l'aide d'une protéine cible sécrétée
EP3842803A1 (fr) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 dans le syndrome des ovaires polykystiques
KR20230041965A (ko) 2020-05-13 2023-03-27 아카우오스, 인크. Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
CN117157108A (zh) 2020-12-29 2023-12-01 阿库斯股份有限公司 用于治疗clrn1相关听力损失和/或视力损失的组合物和方法
AR128422A1 (es) 2022-02-02 2024-05-08 Akouos Inc Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
AU2001239826B2 (en) * 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2004052390A1 (fr) * 2002-12-11 2004-06-24 Amylin Pharmaceuticals, Inc. Methodes et compositions de traitement du syndrome stein-leventhal
GB0702537D0 (en) * 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
CN103845342A (zh) * 2012-12-03 2014-06-11 浙江大学 治疗青春期多囊卵巢综合征合并胰岛素抵抗的组合药物
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
EP3829546A1 (fr) * 2018-08-02 2021-06-09 Hospital Sant Joan de Deu Formulation à libération immédiate d'une triple combinaison d'ingrédients pharmaceutiques actifs utile dans le traitement du syndrome des ovaires polykystiques

Also Published As

Publication number Publication date
MX2018005252A (es) 2018-09-18
RS62764B1 (sr) 2022-01-31
RU2745606C2 (ru) 2021-03-29
KR20180098234A (ko) 2018-09-03
MA54412A (fr) 2021-11-10
WO2017072243A8 (fr) 2018-03-22
AU2016344737B2 (en) 2021-07-08
MX2021007976A (es) 2021-08-16
HUE055778T2 (hu) 2021-12-28
CN108778285A (zh) 2018-11-09
AU2016344737A9 (en) 2018-08-09
EP3368044B1 (fr) 2021-06-09
JP2022009374A (ja) 2022-01-14
WO2017072243A1 (fr) 2017-05-04
BR112018008496A2 (pt) 2018-10-23
IL258876B (en) 2022-03-01
JP2019501113A (ja) 2019-01-17
RU2018119146A (ru) 2019-11-28
MA43106A (fr) 2021-05-05
US20240000804A1 (en) 2024-01-04
US20190060328A1 (en) 2019-02-28
EP3368044A1 (fr) 2018-09-05
TW201720432A (zh) 2017-06-16
JP6999903B2 (ja) 2022-02-04
AU2016344737C1 (en) 2021-10-07
EP3892281A3 (fr) 2021-11-10
AU2016344737A1 (en) 2018-05-17
CA3003076A1 (fr) 2017-05-04
EP3892281A2 (fr) 2021-10-13
GB201518979D0 (en) 2015-12-09
MX384040B (es) 2025-03-14
TWI791420B (zh) 2023-02-11
UY36967A (es) 2017-05-31
DK3368044T3 (da) 2021-09-13
PL3368044T3 (pl) 2021-12-20
WO2017072243A9 (fr) 2018-07-26
AR106505A1 (es) 2018-01-24
CN117379440A (zh) 2024-01-12
ES2883282T3 (es) 2021-12-07
SI3368044T1 (sl) 2022-05-31
RU2018119146A3 (fr) 2020-02-25
CA3003076C (fr) 2023-12-05
LT3368044T (lt) 2021-10-25
IL258876A (en) 2018-06-28
KR102608158B1 (ko) 2023-11-29

Similar Documents

Publication Publication Date Title
MA45819A (fr) Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
MA43335A (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA41013A (fr) Compositions comprenant des souches bactériennes
PH12019550076A1 (en) SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MD3313423T2 (ro) Compoziții care conțin tulpini bacteriene de Blautia pentru tratamentul hipersensibilității viscerale
MA49760B1 (fr) Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique
MX2022015248A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MX395317B (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
PT3597816T (pt) Composições de banho de imersão para o tratamento de insertos de reforço
MX2021007976A (es) Una composicion farmaceutica para usarse en el tratamiento de exceso de grasa hepatica y/o visceral.
MD4685B1 (ro) Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MA53329A (fr) Méthodes de traitement de l'épilepsie
TN2017000534A1 (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
MA46459B1 (fr) Méthode de traitement de lésions rénales aiguës
EP3302474A4 (fr) Compositions pour le traitement de la vaginite atrophique, la dyspareunie péri et post-ménopausique, et/ou de femmes ovariectomisées et procédés de traitement avec celles-ci
EP3344071A4 (fr) Compositions combinées pour réguler des niveaux de glycémie, l'hépatoprotection, et pour la prévention et le traitement d'états médicaux associés
MX2017012610A (es) Composiciones y metodos para inhibir la expresion del gen lect2.
EP3632430A4 (fr) Agent de prévention ou de traitement de l'ataxie spinocérébelleuse
MA43848A (fr) Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
MX2017004842A (es) Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica).
EP3630289A4 (fr) Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies
EP3429567A4 (fr) Procédés et compositions pour traiter l'obésité et/ou le diabète et pour identifier des agents de traitement candidats